Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial-Reference-Cited by-同舟云学术

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Published:2016-08-29 Issue:48 Volume:37 Page:3588-3595
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:Eur Heart J

Author:

Moriarty Patrick M.,Parhofer Klaus G.,Babirak Stephan P.,Cornier Marc-Andre,Duell P. Barton,Hohenstein Bernd,Leebmann Josef,Ramlow Wolfgang,Schettler Volker,Simha Vinaya,Steinhagen-Thiessen Elisabeth,Thompson Paul D.,Vogt Anja,von Stritzky Berndt,Du Yunling,Manvelian Garen

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/37/48/3588/9465146/ehw388.pdf

Reference22 articles.

1. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

2. Quality of life in patients treated with lipoprotein apheresis

3. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

4. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia;Robinson;J Manag Care Pharm,2013

5. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature Review;2024-07-29

2. Efficacy and Safety of Inclisiran, Alirocumab, Evolocumab, and Evinacumab in Lipid-Lowering: A Network Meta-Analysis;2024-04-17

3. Place des inhibiteurs du PCSK9 dans le traitement des hypercholestérolémies;La Presse Médicale Formation;2024-04

4. Prise en charge des patients avec hypercholestérolémie familiale;Archives des Maladies du Coeur et des Vaisseaux - Pratique;2024-03

5. Lipidtherapie bei Patienten mit Diabetes mellitus;Die Diabetologie;2024-01-25